Drugs / Bromocriptine
Bromocriptine
also known as
Cycloset · bromocriptine mesylate · Bromocriptine-QR · B-QR · Bromocriptin · Parlodel · 2-bromo-.alpha.-ergocryptine · 2-bromoergocryptine mesylate · +13 more
Small molecule targets DRD2 via activation
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | PARLODEL | — | 1985-06-28 | fda.gov ↗ |
| Approved | US (FDA) | PARLODEL | — | 1978-06-28 | fda.gov ↗ |
Trials 28
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04128683 | Oct 2020 → Sep 2023 | anorexia nervosa | University of California, San Diego | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT02078440 | Jan 2014 → Jun 2016 | type 2 diabetes mellitus | VeroScience | Completed | No outcome recorded |
| Phase 1 | NCT01821001 | Mar 2013 → Sep 2017 | adenomyosis | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00650520 | May → Jul 2007 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00649168 | Apr → Jun 2007 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03496545 | Nov 2018 → Nov 2019 | intracerebral hemorrhage, ischemic stroke, subarachnoid hemorrhage, traumatic brain injury | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/2 | NCT02696512 | Mar 2016 → Mar 2017 | brain injury | International Brain Research Foundation | Unknown | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT00998556 | Jun 2010 → Mar 2016 | peripartum cardiomyopathy | Hannover Medical School | Completed | Missed primary |
| Phase 2 | NCT00004300 | — | stereotypic movement disorder | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Suspended | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04181385 | Jan 2019 → Jan 2020 | — | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT06250257 | Oct 2024 → May 2026 overdue | dilated cardiomyopathy | Jimma University | Recruiting | No outcome recorded |
| Phase 3 | NCT05405244 | Sep 2017 → Sep 2019 | eating disorder, morbid obesity | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 3 | NCT02133755 | Jul 2014 → Jul 2015 | polycystic ovary syndrome | IWK Health Centre | Unknown | No outcome recorded |
| Phase 3 | NCT00315081 | May 2006 → May 2008 | hyperprolactinemia, schizophrenia | University Hospital, Bonn | Unknown | No outcome recorded |
| Phase 3 | NCT00377676 | Jul 2004 → Jan 2007 | type 2 diabetes mellitus | VeroScience | Completed | No outcome recorded |
| Phase 3 | NCT00240409 | Jul 2003 → Aug 2004 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02172573 | Apr 1999 → Jul 2000 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT03575000 | Jan → Jul 2026 overdue | prediabetes syndrome, schizophrenia | VA Pittsburgh Healthcare System | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT02299050 | Jun 2014 → Apr 2018 | type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 4 | NCT02929485 | Jul 2013 → Jan 2018 | substance dependence | University of California, Berkeley | Withdrawn | No outcome recorded |
| Phase 4 | NCT00451672 | Jan → Dec 2007 | hypertensive disorder, primary aldosteronism | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase not applicable7 trials · 1 met primary | ||||||
| — | NCT04674670 | Nov 2021 → Jul 2023 | fibromyalgia | susanne becker | Completed | No outcome recorded |
| — | NCT04038749 | Jun 2019 → Jul 2022 | lactation disease | Żelazna Medical Centre, LLC | Unknown | No outcome recorded |
| — | NCT03717454 | Dec 2018 → Dec 2021 | prolactin-producing pituitary gland adenoma | Zhebao Wu | Unknown | No outcome recorded |
| — | NCT03714763 | Nov 2018 → Nov 2021 | pituitary gland adenoma | Zhebao Wu | Unknown | No outcome recorded |
| — | NCT03353025 | Jan 2016 → Dec 2025 | prolactin-producing pituitary gland adenoma | First Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT02265484 | Nov 2013 → Jan 2015 | parkinsonian disorder | Institute of Liver and Biliary Sciences, India | Completed | Met primary |
| — | NCT02428933 | Oct 2013 → Feb 2014 | obesity disorder | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Comparator or background therapy18 trials | ||||||
| Phase 1/2 | NCT04413344 Comparator | Jun 2020 → Nov 2021 | Alzheimer disease 4 | Kyoto University | Completed | No outcome recorded |
| Phase 1/2 | NCT03384524 Comparator | Mar 2018 → May 2019 | diabetic macular edema | Andrew Moshfeghi, MD, MBA | Withdrawn | No outcome recorded |
| Phase 2 | NCT04351126 Background | Apr 2019 → Feb 2020 | ovarian hyperstimulation syndrome | Ganin Fertility Center | Completed | No outcome recorded |
| Phase 2 | NCT03525002 Comparator | May 2018 → Aug 2024 | obesity disorder | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 2 | NCT02846493 Comparator | Aug 2016 → Jun 2018 | ovarian hyperstimulation syndrome | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT02544321 Comparator | Sep 2015 → Jun 2019 | type 1 diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2/3 | NCT05565976 Background | Aug 2020 → Dec 2024 | cognitive impairment with or without cerebellar ataxia, ischemic stroke, metabolic syndrome X, vascular dementia | Jaime Daniel Mondragon | Unknown | No outcome recorded |
| Phase 3 | NCT07124221 Comparator | Sep 2025 → Nov 2026 expected | hyperprolactinemia | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT02590601 Comparator | Jan 2017 → Jan 2023 | peripartum cardiomyopathy | Montreal Heart Institute | Withdrawn | No outcome recorded |
| Phase 3 | NCT00441363 Comparator | Feb 2005 → Feb 2006 | type 2 diabetes mellitus | VeroScience | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT05180773 Comparator | Jul 2022 → Jun 2026 overdue | peripartum cardiomyopathy | Dennis M. McNamara, MD, MS | Recruiting | No outcome recorded |
| Phase 4 | NCT04107480 Comparator | Jun 2019 → Mar 2024 | prolactin-producing pituitary gland adenoma | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02682901 Comparator | Oct 2015 → Nov 2018 | diabetic autonomic neuropathy | Eastern Virginia Medical School | Completed | No outcome recorded |
| Phase 4 | NCT01673724 Comparator | Feb 2012 → May 2016 | Parkinson disease | Sandoz | Completed | No outcome recorded |
| Phase 4 | NCT02233023 Comparator | Jun 1998 → Jun 2000 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| — | NCT06556186 Comparator | Oct 2024 → Mar 2027 expected | pituitary tumor | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| — | NCT02428946 Comparator | Oct 2014 → Nov 2015 | — | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| — | NCT01893450 Comparator | Jun 2008 → Jun 2013 | disease of orbital part of eye adnexa | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Terminated | No outcome recorded |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 49 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bromocriptine | “Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12,...” NCT02696512 ↗40“In a few studies and casuistically the treatment of neuroleptic-induced hyperprolactinemia with bromocriptine has been shown to be effective without causing reexacerbation of...” NCT00315081 ↗ “Subjects who show high expression of dopamine D2 receptors in PET-MR imaging will be treated with Cabergoline(CAB) tablets 2mg/week or bromocriptine(BC) tablets 7.5mg/ day.” NCT03714763 ↗ “Current first line treatment consists of a dopamine agonists: cabergoline (currently the most used), bromocriptine or quinagolide.” NCT04107480 ↗ “The dopamine agonist(DA),such as cabergoline(CAB) and bromocriptine(BC), has been used widely in the treatment of prolactinomas” NCT03717454 ↗ “Minimum effective dose of dopamine agonist，bromocriptine，treat prolactinona” NCT03353025 ↗ |
| Known as | 2-bromo-.alpha.-ergocryptine | ChEMBL registry synonym — accepted as the source's own label CHEMBL493 ↗ |
| Known as | 2-bromoergocryptine mesylate | ChEMBL registry synonym — accepted as the source's own label CHEMBL493 ↗ |
| Known as | B-QR | “Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR” NCT02299050 ↗1“Bromocriptine-QR (B-QR), a quick release, sympatholytic, dopamine D2 receptor agonist therapy for T2DM” PMID 28374645 ↗ Apr 2017 |
| Known as | BMC | “Administration of D2 agonist, bromocriptin (BMC), is a standard treatment of prolactinoma” NCT00451672 ↗ |
| Known as | Bromergocryptine | ChEMBL registry synonym — accepted as the source's own label CHEMBL493 ↗ |
| Known as | Bromocriptin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06556186 ↗ |
| Known as | Bromocriptina | ChEMBL registry synonym — accepted as the source's own label CHEMBL493 ↗ |
| Known as | Bromocriptine Mesilate | “Drug: Bromocriptine Mesilate” NCT04413344 ↗ |
| Known as | bromocriptine mesylate | “The objective of this study is to assess the single-dose relative bioavailability of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 2.5 mg...” NCT00650520 ↗2“The pharmacokinetic profile of bromocriptine will be determined following the administration of a single, weight-adjusted dose of CYCLOSET (bromocriptine mesylate) tablets.” NCT02078440 ↗ “Parlodel® (bromocriptine mesylate) capsules, USP 5 mg” NCT00649168 ↗ |
| Known as | Bromocriptine Mesylate Capsules | “Drug: Bromocriptine Mesylate Capsules” NCT04674670 ↗ |
| Known as | Bromocriptine methanesulfonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL493 ↗ |
| Known as | Bromocriptine-QR | “Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR” NCT02299050 ↗2“Quick-release bromocriptine (bromocriptine-QR), a D2 dopamine receptor agonist, is indicated as a treatment for type 2 diabetes.” PMID 20332352 ↗ Mar 2010 “Drug: Bromocriptine-QR” NCT05405244 ↗ |
| Known as | CB-154 | ChEMBL registry synonym — accepted as the source's own label CHEMBL493 ↗ |
| Known as | Cb-154 mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL493 ↗ |
| Known as | CB-154 MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL493 ↗ |
| Known as | Cycloset | “Cycloset” NCT05565976 ↗ |
| Known as | Ergocryptine, 2-bromo- | ChEMBL registry synonym — accepted as the source's own label CHEMBL493 ↗ |
| Known as | NSC-755915 | ChEMBL registry synonym — accepted as the source's own label CHEMBL493 ↗ |
| Known as | Parlodel | “The objective of this study is to assess the single-dose relative bioavailability of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 2.5 mg...” NCT00650520 ↗1“Parlodel® (bromocriptine mesylate) capsules, USP 5 mg” NCT00649168 ↗ |
| Known as | quick-release (QR) bromocriptine (cycloset) | “quick-release (QR) bromocriptine (cycloset)” NCT05405244 ↗ |
| Known as | SANDOZ 15-754 | ChEMBL registry synonym — accepted as the source's own label CHEMBL493 ↗ |
| Action | Activate | “Bromocriptine mesylate, an ergot derivative, is a sympatholytic dopamine D2 receptor agonist” NCT00377676 ↗ |
| Modality | Small molecule | — CHEMBL493 ↗ |
| Route | Oral | “Cycloset, a new quick-release oral formulation” NCT00377676 ↗ |
| Target | DRD2 | “dopamine D2 receptor (DRD2) agonist bromocriptine” NCT05405244 ↗ |